Top Companies in Radiopharmaceuticals Market by Size, Share, Historical and Future Data & CAGR | Report by Vantage Market Research
Radiopharmaceuticals Market is projected to reach a value of USD 9.75 Billion by 2030 at a CAGR of 9.4% over the forecast period.
Coralia.Joe
Vantage Market Research has recently published a new report on "Radiopharmaceuticals Market” Global Industry Assessment & Forecast to identify key trends and challenges. The report offers insights into the competitive landscape, prospects, and key investment considerations for businesses operating in the Radiopharmaceuticals market. Some of the key statistics in the report highlight that Global Radiopharmaceuticals Market was valued at USD 5.2 Billion in 2022 and is projected to reach a value of USD 9.75 Billion by 2030 at a CAGR of 9.4% over the forecast period. The global Radiopharmaceuticals market is expected to grow significantly in the forecast period due to the increasing prevalence of cancer and cardiovascular diseases, growing demand for nuclear medicine, and the ongoing R&D activities in the field of radiopharmaceuticals.
Request Sample Report of Radiopharmaceuticals Market @ https://www.vantagemarketresearch.com/radiopharmaceuticals-market-2143/request-sample
The Global Radiopharmaceuticals market is dominated by well-known players like Bracco Imaging SPA (Italy), Lantheus Medical Imaging Inc. (U.S.), GE Healthcare (U.S.), Siemens Healthineers AG (Germany), Curium Pharma (France), Bracco Imaging (Italy), Nordion Inc. (Canada), Mallinckrodt PLC (U.K.), Jubilant DraxImage Inc. (U.S.), Progenics Pharmaceuticals Inc. (U.S.), among others.
Let’s Take a Look at the Top Market Players that are Captivating the Radiopharmaceuticals Market
- Bracco Imaging SPA (Italy)
Bracco Imaging SPA is a leading provider of diagnostic imaging products and solutions, including radiopharmaceuticals, contrast agents, and medical devices. The company has a strong research and development portfolio focusing on innovation and improving patient outcomes. Bracco Imaging is headquartered in Milan, Italy, and has a global presence in over 100 countries. The radiopharmaceuticals market is a key area of focus for Bracco Imaging, with the company offering a range of products for diagnostic and therapeutic purposes. Bracco Imaging is well-positioned to capitalize on this growth through its strong portfolio of radiopharmaceutical products and its continued investment in research & development. The company is committed to improving patient care and outcomes through its innovative products and solutions, and its expertise in the radiopharmaceuticals market makes it a key player in the industry.
- Lantheus Medical Imaging Inc. (U.S.)
Lantheus Medical Imaging, Inc. is a leading provider of diagnostic imaging agents and therapeutic radiopharmaceuticals. The company offers a wide range of products for diagnostic imaging, including contrast agents for use in MRI, CT, and other imaging modalities. In addition, the company offers radiopharmaceuticals for use in nuclear medicine procedures. Lantheus Medical Imaging, Inc. has a strong presence in the radiopharmaceutical market and is a leader in developing and distributing imaging agents and radiopharmaceuticals. The company has a strong pipeline of products, including new imaging agents and therapeutic radiopharmaceuticals, in various stages of development and clinical trials. In addition to its products, Lantheus Medical Imaging, Inc. also provides a range of services to support its products, including training and education for healthcare professionals, technical support, and regulatory compliance assistance. The company's dedication to innovation, quality, and customer service has made it a trusted provider of diagnostic imaging agents and radiopharmaceuticals to healthcare professionals worldwide.
- GE Healthcare (U.S.)
GE Healthcare is a global leader in medical technology and provides a wide range of products and services related to healthcare. One of the major product portfolios of GE Healthcare is radiopharmaceuticals. GE Healthcare offers a comprehensive range of radiopharmaceuticals such as technetium generators, cyclotron-produced radiopharmaceuticals, PET radiopharmaceuticals, SPECT radiopharmaceuticals, and other radiopharmaceuticals for diagnostics and therapeutics. These radiopharmaceuticals are used in various medical applications such as oncology, cardiology, neurology, and others. GE Healthcare is committed to providing innovative products and services that improve patient outcomes and enhance clinical effectiveness. The company's expertise in medical imaging and radiopharmaceuticals helps healthcare providers diagnose and treat a wide range of diseases.
- Siemens Healthineers AG (Germany)
Siemens Healthineers AG is a leading global provider of medical technology and services. Siemens Healthineers offers a comprehensive portfolio of radiopharmaceuticals, including Technetium-99m (Tc-99m), Fluorine-18 (F-18), Lutetium-177 (Lu-177), and other isotopes. The company also provides state-of-the-art imaging equipment that enables accurate diagnosis and treatment of diseases. The company's strong presence in the radiopharmaceuticals market is primarily due to its innovative products and technologies and its strategic partnerships and collaborations with key players in the industry. Siemens Healthineers is committed to continuing to invest in research and development to advance radiopharmaceuticals and improve patient outcomes.
- Curium Pharma (France)
Curium Pharma is a French company specializing in the production and distribution of radiopharmaceuticals, which are agents used in nuclear medicine to diagnose and treat various diseases. The company was founded in 2017 following the merger of two leading players in the industry, IBA Molecular and Mallinckrodt Nuclear Medicine LLC. Curium Pharma has a global presence in over 60 countries and serves healthcare providers, hospitals, and clinics worldwide.
- Bracco Imaging (Italy)
Bracco Imaging is a global leader in the imaging industry, specializing in diagnostic imaging agents and solutions. Its radiopharmaceutical division offers a comprehensive range of products for the nuclear medicine market, including radiopharmaceuticals for diagnostic and therapeutic use and imaging agents for PET scanning. Bracco Imaging's radiopharmaceutical business has a global presence and provides a wide range of products to meet the evolving needs of its customers. The company's research and development efforts focus on developing innovative diagnostic and therapeutic imaging solutions to improve patient outcomes.
- Nordion Inc. (Canada)
Nordion Inc. is a Canadian company specializing in producing and supplying medical isotopes and radiopharmaceuticals. It provides services to customers in the healthcare industry, including hospitals, clinics, and research institutions worldwide. Nordion Inc. is a leading player in the radiopharmaceuticals market, with a portfolio of products that includes medical isotopes, liquid and solid radiopharmaceuticals, and customized formulation services. The company has established strong partnerships with suppliers, customers, and regulatory bodies to ensure the worldwide safe and reliable supply of radiopharmaceuticals worldwide.
- Mallinckrodt PLC (U.K.)
Mallinckrodt, plc. is a leading global specialty pharmaceutical company based in the United Kingdom. The company's mission is to improve patients' lives through the development, manufacture, and marketing of innovative pharmaceutical products, including radiopharmaceuticals. Mallinckrodt, plc. is a major player in the radiopharmaceuticals market, offering a wide range of products and services. In addition, the company's portfolio also includes imaging agents, therapeutic agents, and contract manufacturing services. Mallinckrodt, plc. is dedicated to innovation and delivering high-quality radiopharmaceuticals that improve patient outcomes.
- Jubilant DraxImage Inc. (U.S.)
Jubilant DraxImage Inc. is a leading provider of radiopharmaceuticals for diagnostic and therapeutic uses. The radiopharmaceutical market is expected to grow significantly in the coming years due to the rising prevalence of cancer and other diseases and the increasing demand for accurate and early diagnosis. The market is also driven by technological advancements in imaging and the development of new radiopharmaceuticals. Jubilant DraxImage Inc. has a strong presence in the radiopharmaceuticals market, offering a wide range of products & services to healthcare providers and patients. The company is committed to developing new and innovative radiopharmaceuticals to help improve patient outcomes and advance the field of medical imaging.
- Progenics Pharmaceuticals Inc (U.S.)
Progenics Pharmaceuticals, Inc is an American biopharmaceutical company specializing in developing and commercializing radiopharmaceuticals. Progenics Pharmaceuticals is focused on developing innovative radiopharmaceuticals for detecting and treating cancer and HIV. The company's lead product, AZEDRA, is a radiotherapeutic drug for treating a rare type of cancer called pheochromocytoma and paraganglioma. Progenics Pharmaceuticals also has a pipeline of other radiopharmaceuticals in various stages of development for the imaging and treatment of prostate cancer, breast cancer, and other solid tumors. Progenics Pharmaceuticals is well-positioned to capitalize on this growth opportunity, given its expertise in radiopharmaceuticals and its strong pipeline of innovative products.
Read Our Latest Blog: Top Companies in Prenatal Genetic Testing Market
Do You Have Any Queries or Specific Requirements? You may enquire to our sales team before purchasing.
Contact us
Eric Kunz
6218 Georgia Avenue NW Ste 1 - 564
Washington DC 20011-5125
United States Tel: +1 202 380 9727
Email: [email protected]
Website: Vantage Market Research
